Methods and materials for assessing prostate cancer therapies and compounds

US7718684B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Michael E. Jung · Los Angeles, US
• Samedy Ouk · San Diego, US
• Charles L. Sawyers · New York, US
• Charlie D. Chen · Los Angeles, US
• Derek Welsbie · Rancho Santa Fe, US

Key dates

• Filing date: Feb 23, 2005
• Grant date: May 18, 2010
• Expiry date: Mar 21, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/426
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.